LPL Financial LLC Lowers Position in Teladoc Health, Inc. (NYSE:TDOC)

LPL Financial LLC lessened its position in Teladoc Health, Inc. (NYSE:TDOC – Get Rating) by 16.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 103,958 shares of the health services provider’s stock after selling 21,162 shares during the quarter. LPL Financial LLC owned approximately 0.06% of Teladoc Health worth $2,459,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. raised its stake in Teladoc Health by 6,223.6% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 212,661 shares of the health services provider’s stock valued at $5,029,000 after buying an additional 209,298 shares during the last quarter. Bogart Wealth LLC lifted its position in Teladoc Health by 28.2% during the fourth quarter. Bogart Wealth LLC now owns 47,845 shares of the health services provider’s stock valued at $1,132,000 after purchasing an additional 10,532 shares in the last quarter. Arete Wealth Advisors LLC purchased a new position in Teladoc Health during the fourth quarter valued at $5,554,440,000. Symmetry Investments LP purchased a new position in Teladoc Health during the fourth quarter valued at $656,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Teladoc Health during the fourth quarter valued at $67,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Analyst Upgrades and Downgrades

TDOC has been the topic of several analyst reports. StockNews.com initiated coverage on Teladoc Health in a research report on Thursday. They set a “sell” rating on the stock. SVB Securities raised Teladoc Health from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research note on Thursday, February 23rd. Citigroup reduced their price objective on Teladoc Health from $33.00 to $30.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 28th. Oppenheimer cut their target price on Teladoc Health from $37.00 to $35.00 and set an “outperform” rating on the stock in a research note on Thursday, February 23rd. Finally, VNET Group reaffirmed a “maintains” rating on shares of Teladoc Health in a research note on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, seventeen have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Teladoc Health presently has a consensus rating of “Hold” and a consensus target price of $32.78.

Insiders Place Their Bets

In other news, insider Adam C. Vandervoort sold 3,877 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $25.36, for a total transaction of $98,320.72. Following the sale, the insider now directly owns 15,629 shares in the company, valued at approximately $396,351.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Adam C. Vandervoort sold 3,877 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $25.36, for a total transaction of $98,320.72. Following the sale, the insider now directly owns 15,629 shares in the company, valued at approximately $396,351.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Richard J. Napolitano sold 1,384 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $25.36, for a total value of $35,098.24. Following the sale, the chief accounting officer now owns 5,030 shares in the company, valued at $127,560.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 58,423 shares of company stock valued at $1,514,860. Company insiders own 1.63% of the company’s stock.

Teladoc Health Price Performance

Shares of TDOC opened at $23.78 on Monday. The business’s 50-day moving average is $25.55 and its two-hundred day moving average is $26.73. The company has a market capitalization of $3.89 billion, a P/E ratio of -0.55 and a beta of 1.08. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.25 and a current ratio of 3.37. Teladoc Health, Inc. has a fifty-two week low of $21.60 and a fifty-two week high of $44.66.

Teladoc Health (NYSE:TDOC – Get Rating) last announced its quarterly earnings results on Wednesday, April 26th. The health services provider reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.14. The company had revenue of $629.24 million for the quarter, compared to the consensus estimate of $617.55 million. Teladoc Health had a negative return on equity of 5.81% and a negative net margin of 285.51%. Research analysts predict that Teladoc Health, Inc. will post -1.38 earnings per share for the current year.

About Teladoc Health

(Get Rating)

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services.